Prof. Ken J. Ishii, M.D., Ph.D., currently Director for Int. Vaccine Design Center, The Institute of Medical Science, the University of Tokyo, has 27 years of experience in Vaccine R&D since 1998 including 7 years as a IND reviewer at US Food and Drug Administration (FDA), 15 years as a basic immunologist at Osaka University, 9 years as a vaccine adjuvant expert at National Institute (NIBIOHN), 2 years as managing director at AMED (medical funding agency), as well as Advisor for G7 100 days mission IPPS, CEPI and several domestic funding agency in Japan. He has contributed to basic research on infectious diseases and immunology, resulted in numerous books and over 290 periodical publications and 42,000 citations with H-index 91 as well as over 50 patents related to vaccine and adjuvant, and to regulation of many vaccines and guidelines for vaccine preclinical and clinical trials in Japan and US.
Topics:
Workshop Chair: Dr David Burkhart, Chief Executive Officer, Inimmune
10:00 Chair’s Opening Remarks
10.10 Self-replicating RNA Platform Development
10.25 Designing the Next Generation of Vaccines: Harnessing Generative AI for In Silico Immunogen Discovery
10.40 A Versatile Platform Technology Enabling Development Of cVLP Vaccines Within Infectious and Non-Communicable Diseases
10:55 Engineering Modular Immunogen Platforms to Neutralize Evolving Chemical Threats
11:10 A Modified Sarna Platform Technology for the Development of A Pan-Filovirus Vaccine
11:25 Killed Whole Cell Genome Reduced Bacterial Vaccines: A New Rapid, Inexpensive, Easily Manufactured, Thermostable Platform
11:40- Q&A
12:00 Panel: The Evolving Landscape of Novel Adjuvant Development – Navigating Safety, Access and Innovation